Tran-Gia, Johannes http://orcid.org/0000-0001-9552-7750
Eberlein, Uta
Lassmann, Michael
Mauz-Körholz, Christine
Körholz, Dieter
Zuccetta, Pietro
Bar-Sever, Zvi
Rosner, Ute
Georgi, Thomas Walter
Sabri, Osama
Kluge, Regine
Piccardo, Arnoldo
Kurch, Lars
Funding for this research was provided by:
Mitteldeutsche Kinderkrebsforschung – Stiftung für Forschung und Heilung, Leipzig, Germany
Universitätsklinikum Würzburg
Article History
Received: 16 June 2023
Accepted: 8 August 2023
First Online: 20 September 2023
Declarations
:
: All patients and/or their guardians provided written informed consent to participate in the EuroNet-PHL-C2 trial. This also included informed consent to provide anonymised data for scientific side projects like our analysis. The Clinical Board of the EuroNet-PHL-C2 study approved this project. An ethics approval was applied to the local ethics committee of the University of Leipzig (065/19-ek). No ethical concerns were expressed. All procedures in connection with this work were performed in accordance with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: M Lassmann has received institutional grants by IPSEN Pharma, Nordic Nanovector and Novartis. No other potential conflicts of interest relevant to this article exist.